Document is current
Any future updates will be listed below
-
Authors
Jurmeister, Philipp https://orcid.org/0000-0001-7745-3794
Weber, Karsten
Villegas, Sonia
Karn, Thomas
Untch, Michael
Thieme, Anne
Müller, Volkmar
Taube, Eliane
Fasching, Peter
Schmitt, Wolfgang D.
Marmé, Frederik
Stickeler, Elmar
Sinn, Bruno V.
Jank, Paul
Schem, Christian
Klauschen, Frederick
van Mackelenbergh, Marion
Denkert, Carsten
Loibl, Sibylle
Capper, David
-
Funding
Funding for this research was provided by:
Deutsches Konsortien für Krebsforschung (EPIC G8)
Deutsche Krebshilfe (INTEGRATE-TN)
- License Information
-
More Information
Article History
Received: 11 April 2021
Accepted: 22 September 2021
First Online: 3 October 2021
Declarations
:
: Ethics approval was granted by the local ethics committee of the Charité – Universitätsmedizin Berlin (EA1/139/05).
: Not applicable.
: Marion van Mackelenbergh reports personal fees from AstraZeneca, personal fees from Amgen, personal fees from Novartis, personal fees from Genomic Health, personal fees from Lilly, personal fees from Pfizer, personal fees from Roche, personal fees from Pierre Fabre, outside the submitted work. All other authors state that there are no competing interests.
